Our Research: Equity in Discovery and Innovation
Leaders in Equal Access to Research Innovation
As world leaders in cancer research discovery and innovation, Dana-Farber is ever mindful that our breakthrough research — and the innovative care that results from that research — needs to be equally accessible to all patient populations, regardless of race, socioeconomics, gender, identity, veteran status, or other differentiators.
This is why, at Dana-Farber, we are deeply committed to:
- Growing our research in cancer disparities
- Increasing minority representation in clinical trials
- Integrating our research findings into clinical care and public health
Some of Our Cancer Disparities Research Initiatives
Cancer Care Equity Program
This program places Dana-Farber at the forefront of efforts to reduce disparities in cancer outcomes for historically marginalized groups locally — and has become a national model for translating cancer equity research into interventions.
Initiative to Eliminate Cancer Disparities
This initiative connects our fellow Harvard institutions to advance our commitment to reducing cancer disparities in cancer prevention, outcomes, care, and survivorship.
Men of African Descent and Carcinoma of the Prostate Consortium
The MADCaP Consortium is collaborating on epidemiologic studies to address the high burden of prostate cancer among men of African ancestry.
Center for Cancer Equity and Engagement
This center works to ensure that the work and research of the Dana-Farber/Harvard Cancer Center reduces the cancer burden and inequity for all Massachusetts residents.
Bona Lab (Pediatric Oncology Health Equity Research)
The mission of this lab's research is to ensure that every child diagnosed with cancer has an equal chance of survival and optimal quality of life during and after treatment.
PROMISE Study
This study seeks to identify people with precursor conditions for multiple myeloma. African Americans are three times more likely than Caucasians to develop these conditions.